CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, today announced the initiation of a Phase 1 trial to test the safety, tolerability, dosing and pharmacokinetics of non-radiolabeled TM601 for the treatment of malignant glioma. The target population for the study is adult patients with progressive and/or recurrent malignant glioma who have failed first-line, standard therapy. Radiolabeled 131Iodine-TM601 is being investigated in multiple cancer types through both local and intravenous delivery, including Phase 2 studies in malignant glioma and metastatic melanoma utilizing intravenous delivery. The current study utilizes an intravenous, unlabeled version of TM601.
